Results 41 to 50 of about 11,837 (160)

Development of Resistance to Eravacycline by Klebsiella pneumoniae and Collateral Sensitivity-Guided Design of Combination Therapies

Microbiology Spectrum, 2022
The evolution of bacterial antibiotic resistance is exhausting the list of currently used antibiotics and endangers those in the pipeline. The combination of antibiotics is a promising strategy that may suppress resistance development and/or achieve ...
Congjuan Xu, Xiaoya Wei, Yongxin Jin, Fang Bai, Zhihui Cheng, Shuiping Chen, Xiaolei Pan, Weihui Wu   +7 more
doaj   +1 more source

Ceftazidime/avibactam versus polymyxin B in carbapenem-resistant Klebsiella pneumoniae infections: a propensity score-matched multicenter real-world study

Infection
In this retrospective observational multicenter study, we aimed to assess efficacy and mortality between ceftazidime/avibactam (CAZ/AVI) or polymyxin B (PMB)-based regimens for the treatment of Carbapenem-resistant Klebsiella pneumoniae (CRKP) infections,
Haiwen Zhuang, Qiang Qu, Wen Long, Qin Hu, Xiao-li Wu, Ying Chen, Qing Wan, Tian-Tian Xu, Yue Luo, Hailing Yuan, Qiong Lu, Jian Qu   +11 more
semanticscholar   +1 more source

An Unusual Case of Citrobacter koseri Infection During Pregnancy at 27 Weeks: A Case Report and Literature Review

Clinical Case Reports, Volume 14, Issue 4, April 2026.
ABSTRACT Early prenatal screening at 26 + 6 weeks detected Citrobacter koseri vaginal colonization in an asymptomatic high‐risk gravida. Culture‐guided IV ceftazidime (susceptible per CLSI testing) eradicated the pathogen without maternal/fetal compromise.
Mario Assenza, Michele Caramia, Jacopo Wabersich   +2 more
wiley   +1 more source

OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs

mSphere, 2019
Infections due to carbapenemase-producing Gram-negative pathogens are associated with limited treatment options and consequently lead to increased mortality and morbidity.
Christopher Fröhlich, Vidar Sørum, Ane Molden Thomassen, Pål Jarle Johnsen, Hanna-Kirsti S. Leiros, Ørjan Samuelsen   +5 more
doaj   +1 more source

Multiple Novel Ceftazidime-Avibactam-Resistant Variants of blaKPC-2-Positive Klebsiella pneumoniae in Two Patients

Microbiology Spectrum, 2022
As the first-line antimicrobial agent for the infection caused by carbapenem-resistant Enterobacterales, ceftazidime-avibactam develops drug resistance during its ever-growing clinical use.
Qingyu Shi, Renru Han, Yan Guo, Yang Yang, Shi Wu, Li Ding, Rong Zhang, Dandan Yin, Fupin Hu   +8 more
doaj   +1 more source

The Evaluation of Machine Learning Models Using Matrix‐Assisted Laser Desorption/Ionization Time‐of‐Flight Mass Spectrometry (MALDI–TOF–MS) Spectra for the Prediction of Antibiotic Resistance in Klebsiella pneumoniae

MicrobiologyOpen, Volume 15, Issue 2, April 2026.
Machine learning models developed from matrix‐assisted laser desorption/ionization time‐of‐flight mass spectrometry spectra can rapidly predict antimicrobial resistance in Klebsiella pneumoniae. By transforming routine spectral data into accurate resistance profiles within minutes, this approach could reduce diagnostic delays and support earlier ...
Stephen Mark Edward Fordham
wiley   +1 more source

German Multicenter Study Analyzing Antimicrobial Activity of Ceftazidime-Avibactam of Clinical Meropenem-Resistant Pseudomonas aeruginosa Isolates Using a Commercially Available Broth Microdilution Assay

Antibiotics, 2022
Multidrug resistance is an emerging healthcare issue, especially concerning Pseudomonas aeruginosa. In this multicenter study, P. aeruginosa isolates with resistance against meropenem detected by routine methods were collected and tested for ...
Jana Manzke, Raphael Stauf, Bernd Neumann, Ernst Molitor, Gunnar Hischebeth, Michaela Simon, Jonathan Jantsch, Jürgen Rödel, Sören L. Becker, Alexander Halfmann, Thomas A. Wichelhaus, Michael Hogardt, Annerose Serr, Christina Hess, Andreas F. Wendel, Ekkehard Siegel, Holger Rohde, Stefan Zimmermann, Jörg Steinmann   +18 more
doaj   +1 more source

Effect of modification of penicillin-binding protein 3 on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of Escherichia coli strains producing broad-spectrum β-lactamases

Antimicrobial Agents and Chemotherapy
The impact of penicillin-binding protein 3 (PBP3) modifications that may be identified in Escherichia coli was evaluated with respect to susceptibility to β-lactam/β-lactamase inhibitor combinations including ceftazidime-avibactam, imipenem-relebactam ...
C. Le Terrier, P. Nordmann, Chloé Buchs, L. Poirel   +3 more
semanticscholar   +1 more source

Bacteriophage Therapy: Current Strategies and Future Perspectives

MedComm, Volume 7, Issue 3, March 2026.
This manuscript systematically reviews the expanding scope of phage applications. It moves beyond traditional antibacterial use to explore their role in precision therapies against drug‐resistant infections, their synergy with antibiotics, and advanced biomaterial‐assisted delivery systems.
Zihe Zhou, Hanyu Fu, Mengzhe Li, Zhongyu Han, Zhenchao Wu, Huahao Fan, Ning Shen, Jiajia Zheng   +7 more
wiley   +1 more source

Rates of resistance to ceftazidime-avibactam and ceftolozane-tazobactam among patients treated for multidrug-resistant Pseudomonas aeruginosa bacteremia or pneumonia.

Clinical Infectious Diseases
Among consecutive patients with multidrug-resistant Pseudomonas aeruginosa bacteremia or pneumonia we found those treated with ceftazidime-avibactam were more likely to develop resistance (defined as ≥4-fold increased MIC) than those treated with ...
Sunish Shah, Ellen G. Kline, G. Haidar, K. Squires, J. Pogue, E. McCreary, Justin Ludwig, L. Clarke, M. Stellfox, D. Van Tyne, R. K. Shields   +10 more
semanticscholar   +1 more source